Hemolytic Complications in Babesia Infections

巴贝虫感染的溶血并发症

基本信息

  • 批准号:
    10220128
  • 负责人:
  • 金额:
    $ 65.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-20 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT: SCD exhibits increased susceptibility to infection which in turn leads to SCD-specific pathophysiological sequelae. Infection is the leading cause of death in these patients especially in less developed countries where the blood supply is not efficiently screened. Even in the US, transfusion transmitted pathogens can represent a major threat of morbidity and mortality to SCD recipients. EVs are produced by pathogens and host cells in response to infection and carry serve as vehicles for dissimilation of effector molecules in the infected host. Hemolysis and anemia are two common symptoms that accompany many infectious diseases. While particularly true of parasitic diseases that target red cells, like malaria and babesia, these complications are also seen in many other infections. While the current proposal focuses on babesia, a single pathogen, we believe that the impact of pathogen derived EVs on host cells is a common theme in the pathogenesis of many infectious diseases and results from this study can have implications for hemolytic complications caused by other infectious agents. Hemolytic complications in SCD are the major contributing pathology to fatalities seen in these transfusion transmissions, making it imperative to elucidate the reason for the higher degree of hemolysis seen in these infected patients. EVs derived from parasitized cells can alter cell membranes, impact gene expression and modulate signaling pathways to promote hemolysis. Our overall goal is to define mechanisms of extracellular vesicle driven hemolysis during infection in SCD, using Babesia as our model. Hypothesis: Babesia anemia is exaggerated in SCD because EVs accelerate a) bystander RBC destruction and b) exacerbate ineffective erythropoiesis due to the increased susceptibility of SCD to 1) EV-mediated alterations and complement opsonization of bystander RBCs resulting in direct /indirect lysis 2) immune activation by EVs resulting in increased phagocytosis and induction of autoAbs 3) EV mediated inhibition of enucleation of erythroid progenitors in SCD BM erythropoiesis. To gain insight into these molecular and cellular processes, using in vivo and in vitro SCD infection models, we will: 1) Elucidate mechanisms by which EV Uptake mediates direct hemolysis by examining EV mediated alterations in membranes of SCD RBCs that cause hemolysis 2) Elucidate mechanisms of EV modulation of extravascular hemolysis by examining macrophage polarization and TLR signaling pathway activation, assessing the role and mechanism of autoAb induction by EVs and determining the contribution of autoantibody opsonization and/or complement fixation in bystander RBC clearance 3) Elucidate mechanisms by which EV Uptake contributes to dyserythropoiesis by defining the underlying molecular mechanisms for both EV-induced and infection- induced enucleation defects in erythroid progenitor cells in SCD bone marrow. Our proposed studies will result in a better understanding of the role of parasite EVs in the pathogenesis associated with human babesiosis especially the hyper- hemolysis seen in the sickle cell context. We anticipate these studies will lead to the refinement of diagnostic tools and offer novel strategies to combat anemia in human babesiosis.
摘要: SCD表现出对感染的易感性增加,进而导致SCD特有的病理生理后遗症。 感染是这些患者的主要死亡原因,特别是在血液供应不发达的欠发达国家 有效的筛选。即使在美国,输血传播的病原体也可能是发病和死亡的主要威胁。 SCD受者的死亡率。肠道病毒是由病原体和宿主细胞对感染作出反应而产生的,并携带 使受感染宿主中的效应器分子异化的载体。溶血和贫血是两种常见的症状 伴随着许多传染病。虽然针对红细胞的寄生虫病尤其如此,如疟疾和 巴贝斯虫,这些并发症也见于许多其他感染。虽然目前的提案重点是巴贝西亚,但单一的 病原体,我们认为病原体来源的EV对宿主细胞的影响是许多疾病发病机制中的共同主题 感染性疾病和这项研究的结果可能对其他传染病引起的溶血性并发症有影响 探员们。SCD的溶血并发症是导致这些输血中死亡的主要病理因素。 因此,必须阐明在这些感染患者中出现较高程度溶血的原因。 来自寄生细胞的EV可以改变细胞膜,影响基因表达,并调节信号通路,从而 促进溶血。我们的总体目标是确定在感染过程中细胞外小泡驱动的溶血机制。 SCD,使用巴贝西亚作为我们的模型。假设:巴贝斯虫贫血在SCD中被夸大,因为EVS加速了 旁观者红细胞破坏和b)由于SCD的易感性增加到1)而加剧无效的红细胞生成 EV介导的旁观者红细胞的改变和补体调理导致直接/间接免疫 EV激活导致吞噬功能增强和诱导自身抗体3)EV介导的去核抑制 红系祖细胞在SCD骨髓造血中的作用。要深入了解这些分子和细胞过程,请使用 体内和体外SCD感染模型,我们将:1)阐明EV摄取介导直接溶血的机制 通过检测EV介导的SCD红细胞膜上导致溶血的改变2)阐明EV的作用机制 巨噬细胞极化和TLR信号通路激活对血管外溶血的调节作用 评价EVS诱导自身抗体的作用和机制及自身抗体的贡献 旁观者红细胞清除中的调理和/或补体结合3)阐明EV摄取的机制 通过定义EV诱导和感染的潜在分子机制来促进红细胞生成障碍- SCD骨髓红系祖细胞诱导的去核缺陷。我们提议的研究将产生更好的 了解肠道寄生虫在人类巴贝斯虫病发病机制中的作用 镰状细胞背景下可见的溶血。我们预计这些研究将导致诊断工具的改进,并提供 防治人类巴贝斯虫病贫血的新策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cheryl Ann Lobo其他文献

Cheryl Ann Lobo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cheryl Ann Lobo', 18)}}的其他基金

Hemolytic Complications in Babesia Infections
巴贝虫感染的溶血并发症
  • 批准号:
    10456797
  • 财政年份:
    2020
  • 资助金额:
    $ 65.22万
  • 项目类别:
Hemolytic Complications in Babesia Infections
巴贝虫感染的溶血并发症
  • 批准号:
    10647738
  • 财政年份:
    2020
  • 资助金额:
    $ 65.22万
  • 项目类别:
Babesia: Extracellular Vesicles and their Role in Intercellular Communication
巴贝斯虫:细胞外囊泡及其在细胞间通讯中的作用
  • 批准号:
    9307089
  • 财政年份:
    2017
  • 资助金额:
    $ 65.22万
  • 项目类别:
Continuous in vitro culture of Babesia microti
田鼠巴贝斯虫体外连续培养
  • 批准号:
    8961269
  • 财政年份:
    2015
  • 资助金额:
    $ 65.22万
  • 项目类别:
Continuous in vitro culture of Babesia microti
田鼠巴贝斯虫体外连续培养
  • 批准号:
    9098833
  • 财政年份:
    2015
  • 资助金额:
    $ 65.22万
  • 项目类别:
Babesiosis: An Emerging Infectious Threat to Transfusion Medicine
巴贝斯虫病:对输血医学的新的感染威胁
  • 批准号:
    8434112
  • 财政年份:
    2011
  • 资助金额:
    $ 65.22万
  • 项目类别:
Babesiosis: An Emerging Infectious Threat to Transfusion Medicine
巴贝斯虫病:对输血医学的新的感染威胁
  • 批准号:
    8243503
  • 财政年份:
    2011
  • 资助金额:
    $ 65.22万
  • 项目类别:
Babesiosis: An Emerging Infectious Threat to Transfusion Medicine
巴贝斯虫病:对输血医学的新的感染威胁
  • 批准号:
    8022336
  • 财政年份:
    2011
  • 资助金额:
    $ 65.22万
  • 项目类别:
Babesiosis: An Emerging Infectious Threat to Transfusion Medicine
巴贝斯虫病:对输血医学的新的感染威胁
  • 批准号:
    8829318
  • 财政年份:
    2011
  • 资助金额:
    $ 65.22万
  • 项目类别:
Babesiosis: An Emerging Infectious Threat to Transfusion Medicine
巴贝斯虫病:对输血医学的新的感染威胁
  • 批准号:
    8645704
  • 财政年份:
    2011
  • 资助金额:
    $ 65.22万
  • 项目类别:

相似海外基金

Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
  • 批准号:
    EP/Y031091/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.22万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.22万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 65.22万
  • 项目类别:
    Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
  • 批准号:
    10715807
  • 财政年份:
    2023
  • 资助金额:
    $ 65.22万
  • 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
  • 批准号:
    MR/Y003667/1
  • 财政年份:
    2023
  • 资助金额:
    $ 65.22万
  • 项目类别:
    Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10740682
  • 财政年份:
    2023
  • 资助金额:
    $ 65.22万
  • 项目类别:
Sjogren's Syndrome Pathogenic Autoantibodies
干燥综合征致病性自身抗体
  • 批准号:
    10854472
  • 财政年份:
    2023
  • 资助金额:
    $ 65.22万
  • 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
  • 批准号:
    487849
  • 财政年份:
    2023
  • 资助金额:
    $ 65.22万
  • 项目类别:
    Operating Grants
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
  • 批准号:
    10481071
  • 财政年份:
    2022
  • 资助金额:
    $ 65.22万
  • 项目类别:
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10526475
  • 财政年份:
    2022
  • 资助金额:
    $ 65.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了